Bristol-Myers Squibb Company (BMY)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 53.60 |
| Open | 53.40 |
| Bid | 53.77 x 900 |
| Ask | 53.95 x 1000 |
| Day's range | 53.30 - 54.01 |
| 52-week range | 39.35 - 57.65 |
| Volume | |
| Avg. volume | 13,787,701 |
| Market cap | 109.398B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.25 |
| Earnings date | 31 Oct 2024 |
| Forward dividend & yield | 2.40 (4.45%) |
| Ex-dividend date | 04 Oct 2024 |
| 1y target est | 52.25 |
ZacksBristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
Business WireU.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J., October 03, 2024--U.S. FDA Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo...
Investor's Business DailyBristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
© 2024 Yahoo. All rights reserved.